196 related articles for article (PubMed ID: 35789981)
1. Colorectal cancer-derived exosomes and modulation KRAS signaling.
Wan YH; Liu QS; Wan SS; Wang RW
Clin Transl Oncol; 2022 Nov; 24(11):2074-2080. PubMed ID: 35789981
[TBL] [Abstract][Full Text] [Related]
2. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G; Pei L; Xia H; Tang Q; Bi F
Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
[TBL] [Abstract][Full Text] [Related]
3. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
4. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
5. Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression.
Shang A; Gu C; Zhou C; Yang Y; Chen C; Zeng B; Wu J; Lu W; Wang W; Sun Z; Li D
Cell Commun Signal; 2020 Mar; 18(1):52. PubMed ID: 32228650
[TBL] [Abstract][Full Text] [Related]
6. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
7. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
8. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
Wu K; Wu B; Yan K; Ding Q; Miao Z
Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.
Liu X; Wang Y; Zhao J
Oncol Rep; 2017 Nov; 38(5):3187-3196. PubMed ID: 29048669
[TBL] [Abstract][Full Text] [Related]
11. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
12. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
13. KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.
Hao YX; Li YM; Ye M; Guo YY; Li QW; Peng XM; Wang Q; Zhang SF; Zhao HX; Zhang H; Li GH; Zhu JH; Xiao WH
Oncol Lett; 2017 May; 13(5):3608-3616. PubMed ID: 28521461
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
[TBL] [Abstract][Full Text] [Related]
15. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
[TBL] [Abstract][Full Text] [Related]
16. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Ates O; Yalcin S
Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
[TBL] [Abstract][Full Text] [Related]
17. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
18. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
19. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
20. Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming.
Velez-Delgado A; Donahue KL; Brown KL; Du W; Irizarry-Negron V; Menjivar RE; Lasse Opsahl EL; Steele NG; The S; Lazarus J; Sirihorachai VR; Yan W; Kemp SB; Kerk SA; Bollampally M; Yang S; Scales MK; Avritt FR; Lima F; Lyssiotis CA; Rao A; Crawford HC; Bednar F; Frankel TL; Allen BL; Zhang Y; Pasca di Magliano M
Cell Mol Gastroenterol Hepatol; 2022; 13(6):1673-1699. PubMed ID: 35245687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
